BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9020367)

  • 21. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
    Taylor VC; Sims M; Brett S; Field MC
    Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
    Dyer MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
    Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
    J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.
    Brett S; Baxter G; Cooper H; Johnston JM; Tite J; Rapson N
    Immunology; 1996 May; 88(1):13-9. PubMed ID: 8707338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A personal history of the CAMPATH-1H antibody.
    Waldmann H
    Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
    Osterborg A; Mellstedt H; Keating M
    Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
    Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia].
    de Nully Brown P; Hansen MM; Nissen NI
    Ugeskr Laeger; 1997 Jul; 159(28):4389-93. PubMed ID: 9235735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
    Schriever F; Huhn D
    Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
    Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
    PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.